David is a biopharmaceutical executive and industry veteran, with over 30 years of experience, in large, mid-size, small, and start-up companies. His experience includes the commercialization of five medications with annual sales in excess of $1 billion each, including Adderall XR® and Vyvanse®, the two most successful ADHD brands based on annual revenue. He currently runs a consulting practice advising life science companies and is an angel investor with Robin Hood Ventures

David served as President & CEO of Vallon Pharmaceuticals (NASDAQ: VLON), a company he co-founded in 2018 and took public in 2021, before leading the company through a successful merger in 2023.  During his time at Vallon, he built the management team, raised over $30 million, advanced a lead asset from the pre-clinical stage to the late stages of clinical development, and secured a European partnership. 

David was the Chief Commercial Officer and CEO of Alcobra Ltd., an Israeli pharmaceutical company based in Tel Aviv, which merged with Arcturus Therapeutics in 2017. He previously worked at Shire Plc for 10 years as Vice President of Commercial Strategy and New Business in the Neuroscience Business Unit, Global General Manager for Vyvanse® and Vice President, ADHD Marketing. David began his career at Merck where he worked for over a decade in marketing, sales, market research, and business development. 

David serves on the boards of GRI Bio (NASDAQ: GRI), Devonian Health Group (TSXV: GSD; OTCQB: DVHGF).  Additionally, he serves as the President of the non-profit Philadelphia Israel Chamber of Commerce (PICC). David earned a BA in Economics and Computer Science from Duke University, and an MBA in Marketing, from Duke’s Fuqua School of Business.